Log In Sign up
The largest database of trusted experimental protocols

Phospho p44 42 mapk erk1 2 thr 202 tyr 204 l34f12

Manufactured by Cell Signaling Technology
Visit Supplier

The Phospho-p44/42 MAPK (ERK1/2) (Thr 202/Tyr 204) (L34F12) is a lab equipment product used to detect and quantify the phosphorylation of p44/42 MAPK (ERK1/2) at the Thr202 and Tyr204 residues. It is a key component in the analysis of MAPK signaling pathways.

Automatically generated - may contain errors

Lab products found in correlation

Chameleon duo pre stained protein ladder, by LI COR (2 mentions) Odyssey clx imaging system, by LI COR (2 mentions) Tyrosine hydroxylase, by Merck Group (2 mentions) Pan p44 42 mapk erk1 2, by Cell Signaling Technology (2 mentions) P44 42 mapk control cell extracts, by Cell Signaling Technology (2 mentions) β actin, by Merck Group (2 mentions) Trans blot turbo transfer system, by Bio-Rad (2 mentions)

2 protocols using phospho p44 42 mapk erk1 2 thr 202 tyr 204 l34f12

1

Quantifying Striatal Protein Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
All striatal tissue was run on Any-kD MiniProtean® TGX™ precast gels, transferred with a Trans-Blot TurboTransfer System (Bio-Rad Laboratories, Hercules, CA), Chameleon® Duo Pre-stained Protein Ladder was used for size reference, blots were scanned on an Odyssey CLx imaging system, (LI-COR, Lincoln, NE) and analyzed with Empiria Studio Software according to the manufacturers respective recommendations. Tissue homogenate samples from the striata of dyskinetic rats in Experiment 1 were loaded with a two-fold dilution from 64 to 0.5 μg to determine a linear range for each protein, and 5–15 μg of protein was loaded on each gel with a positive and negative control. Primary antibodies: Phospho-p44/42 MAPK (ERK1/2) (Thr 202/Tyr 204) (L34F12) (1:2000), Pan-p44/42 MAPK (ERK1/2) (1:2000) (Cell Signaling Technology, Danvers, MA). Tyrosine Hydroxylase (1:2000) (Millipore, Billerica, MA). Beta-Actin (1:10,000) (Sigma-Aldrich). LICOR secondary antibodies: IRDye® 800 CW Donkey anti-Rabbit (1:10,000), IRDye® 680 CW Donkey anti-Mouse (1:10,000). Controls: p44/42 MAPK control cell extracts (Cell Signaling Technology).
Bartlett M.J., Flores A.J., Ye T., Smidt S.I., Dollish H.K., Stancati J.A., Farrell D.C., Parent K.L., Doyle K.P., Besselsen D.G., Heien M.L., Cowen S.L., Steece-Collier K., Sherman S.J, & Falk T. (2020). Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental neurology, 333, 113413.
+ Open protocol
+ Expand
2

Quantifying Striatal Protein Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
All striatal tissue was run on Any-kD MiniProtean® TGX™ precast gels, transferred with a Trans-Blot TurboTransfer System (Bio-Rad Laboratories, Hercules, CA), Chameleon® Duo Pre-stained Protein Ladder was used for size reference, blots were scanned on an Odyssey CLx imaging system, (LI-COR, Lincoln, NE) and analyzed with Empiria Studio Software according to the manufacturers respective recommendations. Tissue homogenate samples from the striata of dyskinetic rats in Experiment 1 were loaded with a two-fold dilution from 64 to 0.5 μg to determine a linear range for each protein, and 5–15 μg of protein was loaded on each gel with a positive and negative control. Primary antibodies: Phospho-p44/42 MAPK (ERK1/2) (Thr 202/Tyr 204) (L34F12) (1:2000), Pan-p44/42 MAPK (ERK1/2) (1:2000) (Cell Signaling Technology, Danvers, MA). Tyrosine Hydroxylase (1:2000) (Millipore, Billerica, MA). Beta-Actin (1:10,000) (Sigma-Aldrich). LICOR secondary antibodies: IRDye® 800 CW Donkey anti-Rabbit (1:10,000), IRDye® 680 CW Donkey anti-Mouse (1:10,000). Controls: p44/42 MAPK control cell extracts (Cell Signaling Technology).
Bartlett M.J., Flores A.J., Ye T., Smidt S.I., Dollish H.K., Stancati J.A., Farrell D.C., Parent K.L., Doyle K.P., Besselsen D.G., Heien M.L., Cowen S.L., Steece-Collier K., Sherman S.J, & Falk T. (2020). Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia. Experimental neurology, 333, 113413.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!